Tcr2 Therapeutics Ownership
Tcr2 Therapeutics shows a total of 39.26 Million outstanding shares. Over half of Tcr2 Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tcr2 |
Tcr2 Stock Ownership Analysis
About 54.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tcr2 Therapeutics recorded a loss per share of 4.2. The entity had not issued any dividends in recent years. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Tcr2 Therapeutics contact Dr MBA at 617 949 5200 or learn more at https://www.tcr2.com.Tcr2 Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tcr2 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tcr2 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tcr2 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mpm Sunstates Fund Lp over a year ago Acquisition or disposition of Tcr2 Therapeutics securities by Mpm Sunstates Fund Lp | ||
Peter Olagunju over a year ago Disposition of 24092 shares by Peter Olagunju of Tcr2 Therapeutics subject to Rule 16b-3 | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 50000 shares of Tcr2 Therapeutics | ||
Mpm Asset Management Llc over a year ago Exercise of in-the-money or at-the-money derivative position by Mpm Asset Management Llc of 135508 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 38765 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 57073 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Tcr2 Therapeutics exotic insider transaction detected |
Tcr2 Therapeutics Outstanding Bonds
Tcr2 Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tcr2 Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tcr2 bonds can be classified according to their maturity, which is the date when Tcr2 Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US878091BD86 Corp BondUS878091BD86 | View | |
| US878091BG18 Corp BondUS878091BG18 | View | |
| US878091BF35 Corp BondUS878091BF35 | View | |
| US878091BC04 Corp BondUS878091BC04 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Pair Trading with Tcr2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to News Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace News Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back News Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling News Corp A to buy it.
The correlation of News Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as News Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if News Corp A moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for News Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |